PURPOSE: Studies of non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular events using administrative data require identification of incident acute myocardial infarctions (AMIs) and information on whether confounders differ by NSAID status. METHODS: We identified patients with a first AMI hospitalization from Tennessee Medicaid files as those with primary ICD-9 discharge diagnosis 410.x and hospitalization stay of > 2 calendar days. Eligible persons were non-institutionalized, aged 50-84 years between 1999-2004, had continuous enrollment and no AMI, stroke, or non-cardiovascular serious medical illness in the prior year. Of 5524 patients with a potential first AMI, a systematic sample (n = 350) was selected for review. Using defined criteria, we classified events using chest pain history, EKG, and cardiac enzymes, and calculated the positive predictive value (PPV) for definite or probable AMI. RESULTS: 337 of 350 (96.3%) charts were abstracted and 307 (91.1%), 6 (1.8%), and 24 (7.1%) events were categorized as definite, probable, and no AMI, respectively. PPV for any definite or probable AMI was 92.8% (95% CI 89.6-95.2); for an AMI without an event in the past year 91.7% (95% CI 88.3-94.2), and for an incident AMI was 72.7% (95% CI 67.7-77.2). Age-adjusted prevalence of current smoking (46.4% vs. 39.1%, p = 0.35) and aspirin use (36.9% vs. 35.9%, p = 0.90) was similar among NSAID users and non-users CONCLUSIONS: ICD-9 code 410.x had high predictive value for identifying AMI. Among those with AMI, smoking and aspirin use was similar in NSAID exposure groups, suggesting these factors will not confound the relationship between NSAIDs and cardiovascular outcomes. (c) 2009 John Wiley & Sons, Ltd.
PURPOSE: Studies of non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular events using administrative data require identification of incident acute myocardial infarctions (AMIs) and information on whether confounders differ by NSAID status. METHODS: We identified patients with a first AMI hospitalization from Tennessee Medicaid files as those with primary ICD-9 discharge diagnosis 410.x and hospitalization stay of > 2 calendar days. Eligible persons were non-institutionalized, aged 50-84 years between 1999-2004, had continuous enrollment and no AMI, stroke, or non-cardiovascular serious medical illness in the prior year. Of 5524 patients with a potential first AMI, a systematic sample (n = 350) was selected for review. Using defined criteria, we classified events using chest pain history, EKG, and cardiac enzymes, and calculated the positive predictive value (PPV) for definite or probable AMI. RESULTS: 337 of 350 (96.3%) charts were abstracted and 307 (91.1%), 6 (1.8%), and 24 (7.1%) events were categorized as definite, probable, and no AMI, respectively. PPV for any definite or probable AMI was 92.8% (95% CI 89.6-95.2); for an AMI without an event in the past year 91.7% (95% CI 88.3-94.2), and for an incident AMI was 72.7% (95% CI 67.7-77.2). Age-adjusted prevalence of current smoking (46.4% vs. 39.1%, p = 0.35) and aspirin use (36.9% vs. 35.9%, p = 0.90) was similar among NSAID users and non-users CONCLUSIONS: ICD-9 code 410.x had high predictive value for identifying AMI. Among those with AMI, smoking and aspirin use was similar in NSAID exposure groups, suggesting these factors will not confound the relationship between NSAIDs and cardiovascular outcomes. (c) 2009 John Wiley & Sons, Ltd.
Authors: Seoyoung C Kim; Sebastian Schneeweiss; Niteesh Choudhry; Jun Liu; Robert J Glynn; Daniel H Solomon Journal: Am J Med Date: 2015-02-03 Impact factor: 4.965
Authors: Montika Bush; Til Stürmer; Sally C Stearns; Ross J Simpson; M Alan Brookhart; Wayne Rosamond; Anna M Kucharska-Newton Journal: Pharmacoepidemiol Drug Saf Date: 2018-02-06 Impact factor: 2.890
Authors: Nam-Kyong Choi; Daniel H Solomon; Theodore N Tsacogianis; Joan E Landon; Hong Ji Song; Seoyoung C Kim Journal: J Bone Miner Res Date: 2017-02-07 Impact factor: 6.741
Authors: Sarah L Cutrona; Sengwee Toh; Aarthi Iyer; Sarah Foy; Elizabeth Cavagnaro; Susan Forrow; Judith A Racoosin; Robert Goldberg; Jerry H Gurwitz Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Daniel H Solomon; Jeffrey R Curtis; Kenneth G Saag; Joyce Lii; Lang Chen; Leslie R Harrold; Lisa J Herrinton; David J Graham; Mary K Kowal; Bindee Kuriya; Liyan Liu; Marie R Griffin; James D Lewis; Jeremy A Rassen Journal: Am J Med Date: 2013-08 Impact factor: 4.965
Authors: Sarah L Cutrona; Sengwee Toh; Aarthi Iyer; Sarah Foy; Gregory W Daniel; Vinit P Nair; Daniel Ng; Melissa G Butler; Denise Boudreau; Susan Forrow; Robert Goldberg; Joel Gore; David McManus; Judith A Racoosin; Jerry H Gurwitz Journal: Pharmacoepidemiol Drug Saf Date: 2012-06-29 Impact factor: 2.890
Authors: Kurt Niesner; Harvey J Murff; Marie R Griffin; Brian Wasserman; Robert Greevy; Carlos G Grijalva; Christianne L Roumie Journal: Epidemiology Date: 2013-03 Impact factor: 4.822
Authors: Emily S Brouwer; Sonia Napravnik; Joseph J Eron; Ross J Simpson; M Alan Brookhart; Brant Stalzer; Michael Vinikoor; Michelle Floris-Moore; Til Stürmer Journal: Med Care Date: 2015-06 Impact factor: 2.983